Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Pancreatic Cells Derived from Human Embryonic Stem Cells Cure Diabetes in Rodent Models

By BiotechDaily International staff writers
Posted on 12 Jul 2012
Print article
Commercially available human embryonic stem cells (hESCs) have been induced to differentiate into fully functional pancreatic beta cells that were capable of restoring insulin production and regularizing glucose metabolism in two different rodent diabetes models.

Investigators at the University of British Columbia (Vancouver, Canada) and their colleagues at the biotechnology firm BetaLogics (Raritan, NJ, USA) developed a protocol to differentiate commercially available human embryonic stem cells (hESCs) in vitro into a highly enriched PDX1+ pancreatic progenitor cell population. These cells progressed in vivo into mature pancreatic endocrine cells.

Immature pancreatic precursor cells were transplanted into immunodeficient mice with streptozotocin-induced diabetes. Glycemia was initially controlled with exogenous insulin; however, as insulin levels derived from the grafted stem cells increased over time, the mice were weaned from the insulin. Glucose metabolism was eventually regulated by meal and glucose challenges. Similar differentiation of pancreatic precursor cells was observed after transplant into immunodeficient rats.

Additional details published in the June 27, 2012, online edition of the journal Diabetes revealed that throughout the in vivo maturation period hESC-derived endocrine cells exhibited gene and protein expression profiles that were remarkably similar to that of cells in the developing human fetal pancreas.

"We are very excited by these findings, but additional research is needed before this approach can be tested clinically in humans," said senior author Dr. Timothy Kieffer, professor of cellular and physiological sciences at the University of British Columbia. "The studies were performed in diabetic mice that lacked a properly functioning immune system that would otherwise have rejected the cells. We now need to identify a suitable way of protecting the cells from immune attack so that the transplant can ultimately be performed in the absence of any immunosuppression."

Related Links:
University of British Columbia
BetaLogics


Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.